Department of Internal Medicine, Faculty of Medicine, Cukurova University, 01330, Adana, Turkey.
Clin Exp Nephrol. 2010 Feb;14(1):22-7. doi: 10.1007/s10157-009-0214-2. Epub 2009 Oct 1.
Nonsteroidal anti-inflammatory drugs act by inhibiting the rate-limiting enzymes cyclooxygenase-1 (Cox-1) and cyclooxygenase-2 (Cox-2), which are important in prostanoid formation. The aim of this experimental study was to examine the effects of selective Cox-2 inhibitor, rofecoxib, with or without furosemide, on urine and serum electrolytes, creatinine clearance, plasma renin activity (PRA), and Cox-2 expression in the renal cortex.
Forty male Wistar albino rats were randomized into four groups, group 1, group 2, group 3, and group 4, and were treated with placebo, furosemide (20 mg/kg), rofecoxib (10 mg/kg) plus furosemide (12 mg/kg), and rofecoxib (10 mg/kg), respectively, and followed for 7 days. Body weights were measured daily. Urine osmolality and volume, and serum and urinary creatinine, sodium (Na(+)), and potassium (K(+)) were measured. Renal cortical Cox-2 protein expression was examined by immunohistochemical method.
Compared with groups 1 and 3, body weights were significantly reduced in groups 2 and 4 (16.2 and 19.8 g, respectively; P < 0.05 for all). Urine volume in group 2 increased significantly compared with groups 1, 3, and 4 (P < 0.001, P < 0.008, and P < 0.004, respectively). Urine osmolality in group 2 decreased significantly compared with groups 1 and 3 (P < 0.05 for all). Blood urea nitrogen, serum creatinine and sodium, creatinine clearance, and 24-h urine Na(+) and K(+) levels were similar in all groups. Serum K(+) level was lowest in group 2, and there was a statistically significant difference between groups 2 and 4 (P < 0.05). Plasma renin activity was similar in all groups (P > 0.05). Renal cortical Cox-2 protein expression was lowest in group 1 and was significantly different from the other groups (P < 0.01 for all). The relationship between Cox-2 expression and plasma renin activity was not significant in any group (P > 0.05, r(2):0.05).
Rofecoxib neutralized the diuretic effect of furosemide in rats treated with a combination of furosemide and rofecoxib. Renal cortical Cox-2 protein expressions due to furosemide and rofecoxib with or without furosemide were similar and significantly increased compared with controls. Renal failure due to rofecoxib did not developed in any rat, but selective Cox-2 inhibitor, rofecoxib, might have similar renal effects as nonselective nonsteroidal drugs for blunting the diuretic effect of furosemide.
非甾体类抗炎药通过抑制前列腺素形成过程中的限速酶环氧化酶-1(Cox-1)和环氧化酶-2(Cox-2)发挥作用。本实验研究旨在探讨选择性 Cox-2 抑制剂罗非昔布联合或不联合呋塞米对尿和血清电解质、肌酐清除率、血浆肾素活性(PRA)以及肾皮质 Cox-2 表达的影响。
40 只雄性 Wistar 白化大鼠随机分为 4 组,第 1 组、第 2 组、第 3 组和第 4 组,分别给予安慰剂、呋塞米(20mg/kg)、罗非昔布(10mg/kg)加呋塞米(12mg/kg)和罗非昔布(10mg/kg)治疗,随访 7 天。每天测量体重。测量尿渗透压和尿量以及血清和尿肌酐、钠(Na(+))和钾(K(+))水平。通过免疫组织化学方法检测肾皮质 Cox-2 蛋白表达。
与第 1 组和第 3 组相比,第 2 组和第 4 组的体重明显减轻(分别为 16.2g 和 19.8g;P<0.05 均)。与第 1 组、第 3 组和第 4 组相比,第 2 组的尿量明显增加(P<0.001、P<0.008 和 P<0.004,均)。与第 1 组和第 3 组相比,第 2 组的尿渗透压明显降低(P<0.05 均)。各组的血尿素氮、血清肌酐和钠、肌酐清除率以及 24 小时尿 Na(+)和 K(+)水平相似。第 2 组的血清 K(+)水平最低,与第 2 组和第 4 组之间存在统计学差异(P<0.05)。各组的血浆肾素活性相似(P>0.05)。第 1 组的肾皮质 Cox-2 蛋白表达最低,与其他组差异显著(P<0.01 均)。在任何一组中,Cox-2 表达与血浆肾素活性之间均无显著相关性(P>0.05,r(2):0.05)。
罗非昔布拮抗了呋塞米联合罗非昔布治疗大鼠的利尿作用。呋塞米和罗非昔布联合或不联合呋塞米引起的肾皮质 Cox-2 蛋白表达相似且明显高于对照组。罗非昔布未引起任何大鼠肾衰竭,但选择性 Cox-2 抑制剂罗非昔布可能具有与非选择性非甾体抗炎药类似的肾脏作用,可减弱呋塞米的利尿作用。